Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

rally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions.  Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.  These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2013.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statem
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... PHILADELPHIA , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite ... scientific, technical and medical information products and services, announced today ... -based clinical decision support (CDS) technology company. InferMed,s ...
(Date:7/1/2015)... 1, 2015  UCB, a multinational biopharmaceutical company, ... leader in designing, transforming, and running intelligent business ... recognition of their close collaboration in driving transformation ... business services (GBS) finance organization. The ... that work together effectively to embrace the innovative ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... Fluorescence activated cell sorting (FACS) is a , tool ... individual cells using fluorescent probes that bind specifically to molecules , ... cells of a given population down to the level of a ... Figure 1.Linear Amplification from 1-1000 Cells. , ...
... Isolate and Enrich for ... Isolating Bacterial RNA for Microarray Analysis , The rapid increase in , ... several years has opened up a new ... analysis using DNA microarray technology. In recent , ...
... NEW Cyanobacterial Module , ... MICROB Express (patent pending) is currently the , ... novel strategy that rapidly removes >95% of the 16S and 23S rRNA from , ... species , (Figure 1). MICROB Express can ...
Cached Biology Technology:Cells-to-cDNA II Using FACS Sorted Cells 2Bacterial Whole Genome Array Analysis 2Bacterial Whole Genome Array Analysis 3Bacterial Whole Genome Array Analysis 4Bacterial Whole Genome Array Analysis 5Bacterial Whole Genome Array Analysis 6Bacterial Whole Genome Array Analysis 7Bacterial mRNA Isolation, Fast and Easy 2Bacterial mRNA Isolation, Fast and Easy 3
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/16/2015)... CITY , June 16, 2015 /CNW Telbec/ ... their partnership centralized around the incorporation of handyem,s ... point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented model ... BIO International Conference at the Pennsylvania ... from June 15 th to 18 ...
(Date:6/15/2015)... 2015 A new report [ ... majority of US consumers using mobile banking applications want their ... fingerprint and voiceprint, instead of having to prove who they ... " Mobile Identity   -   The Fusion of Financial ... now the primary channel used by Gen X and Gen ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... damage that normally heals on its own will not ... land that release industrial chemicals, fuel oils and other ... colleagues have found. , UCF associate professor of biology ... Institute, Broward County Department of Environmental Protection, the College ...
... Wolbachia have long been interested in its ability to proliferate. ... of its insect hosts and genetically tricking them to bear ... Now, a new study from the MBL (Marine Biological ... demonstrates that a virus common to Wolbachia cells may be ...
... Neuroscientists at the Case Western Reserve University School ... in the brain's immune cells triggers a cascade ... that eventually leads to the neural cell death ... their findings in the Journal of Biological Chemistry ...
Cached Biology News:Pollution threatens coral health by preventing lesions from healing, UCF study shows 2Pollution threatens coral health by preventing lesions from healing, UCF study shows 3Viral hitchhiker inhibits Wolbachia bacteria's ability to proliferate 2Case Western Reserve University researchers find protein associated with brain cell death 2
... emerging as a powerful new tool for ... only amino groups have been able to ... as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and its ... to the protein interaction tool chest that ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Biology Products: